These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Gandhi V; Estey E; Keating MJ; Chucrallah A; Plunkett W Blood; 1996 Jan; 87(1):256-64. PubMed ID: 8547650 [TBL] [Abstract][Full Text] [Related]
4. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616 [TBL] [Abstract][Full Text] [Related]
5. Determination of 2-chloro-2'-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography. Reichelova V; Albertioni F; Liliemark J J Chromatogr B Biomed Appl; 1996 Jun; 682(1):115-23. PubMed ID: 8832432 [TBL] [Abstract][Full Text] [Related]
6. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Begleiter A; Verburg L; Ashique A; Lee K; Israels LG; Mowat MR; Johnston JB Leukemia; 1995 Nov; 9(11):1875-81. PubMed ID: 7475278 [TBL] [Abstract][Full Text] [Related]
7. Resistance to 2-chloro-2'-deoxyadenosine of the human B-cell leukemia cell line EHEB. Cardoen S; Van Den Neste E; Smal C; Rosier JF; Delacauw A; Ferrant A; Van den Berghe G; Bontemps F Clin Cancer Res; 2001 Nov; 7(11):3559-66. PubMed ID: 11705877 [TBL] [Abstract][Full Text] [Related]
8. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. Alessi-Severini S; Gati WP; Belch AR; Paterson AR Leukemia; 1995 Oct; 9(10):1674-9. PubMed ID: 7564508 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Johnston JB Leuk Lymphoma; 2011 Jun; 52 Suppl 2():43-5. PubMed ID: 21463108 [TBL] [Abstract][Full Text] [Related]
10. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Chandra J; Mansson E; Gogvadze V; Kaufmann SH; Albertioni F; Orrenius S Blood; 2002 Jan; 99(2):655-63. PubMed ID: 11781251 [TBL] [Abstract][Full Text] [Related]
11. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. Lindemalm S; Liliemark J; Gruber A; Eriksson S; Karlsson MO; Wang Y; Albertioni F Haematologica; 2003 Mar; 88(3):324-32. PubMed ID: 12651272 [TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Liliemark J; Juliusson G Clin Cancer Res; 1995 Apr; 1(4):385-90. PubMed ID: 9815995 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. Saven A; Cheung WK; Smith I; Moyer M; Johannsen T; Rose E; Gollard R; Kosty M; Miller WE; Piro LD J Clin Oncol; 1996 Mar; 14(3):978-83. PubMed ID: 8622049 [TBL] [Abstract][Full Text] [Related]
14. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission. Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616 [TBL] [Abstract][Full Text] [Related]
15. Study of the efficacy of a pronucleotide of 2-chloro-2'-deoxyadenosine in deoxycytidine kinase-deficient lymphoma cells. Bontemps F; Meier C; Delacauw A; Balzarini J; Galmarini C; van den Neste E Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):997-1000. PubMed ID: 17065053 [TBL] [Abstract][Full Text] [Related]
16. A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. Liliemark J; Albertioni F; Juliusson G; Eksborg S Cancer Chemother Pharmacol; 1996; 38(6):536-40. PubMed ID: 8823495 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. Lindemalm S; Liliemark J; Juliusson G; Larsson R; Albertioni F Cancer Lett; 2004 Jul; 210(2):171-7. PubMed ID: 15183532 [TBL] [Abstract][Full Text] [Related]
18. 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Robak T; Błasińska-Morawiec M; Błoński JZ; Dmoszyńska A Leuk Lymphoma; 1999 Jun; 34(1-2):151-7. PubMed ID: 10350343 [TBL] [Abstract][Full Text] [Related]
19. On the phosphorylation of 2-chlorodeoxyadenosine (CdA) and its correlation with clinical response in leukemia treatment. Arnér ES Leuk Lymphoma; 1996 Apr; 21(3-4):225-31. PubMed ID: 8726403 [TBL] [Abstract][Full Text] [Related]
20. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Robak T; Blonski JZ; Gora-Tybor J; Kasznicki M; Konopka L; Ceglarek B; Komarnicki M; Lewandowski K; Hellmann A; Lewandowski K; Moskwa A; Dmoszyńska A; Sokołowska B; Dwilewicz-Trojaczek A; Tomaszewska A; Sułek K; Całbecka M Eur J Cancer; 2004 Feb; 40(3):383-9. PubMed ID: 14746857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]